iCAD (NASDAQ:ICAD - Get Free Report) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Wednesday.
iCAD Stock Down 3.7 %
Shares of ICAD stock traded down $0.08 on Wednesday, hitting $2.06. The stock had a trading volume of 85,620 shares, compared to its average volume of 251,280. The business has a 50 day moving average price of $2.68 and a 200 day moving average price of $2.08. iCAD has a one year low of $1.18 and a one year high of $3.78. The company has a market cap of $54.67 million, a PE ratio of -15.92 and a beta of 1.95.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The business had revenue of $5.41 million for the quarter, compared to analysts' expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
Institutional Trading of iCAD
A number of institutional investors have recently modified their holdings of ICAD. Granahan Investment Management LLC acquired a new stake in iCAD in the fourth quarter valued at approximately $96,000. Integrated Wealth Concepts LLC purchased a new stake in shares of iCAD during the 4th quarter valued at $92,000. Wells Fargo & Company MN boosted its position in shares of iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after purchasing an additional 13,402 shares in the last quarter. Perritt Capital Management Inc grew its stake in iCAD by 1.9% during the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after buying an additional 3,600 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in iCAD by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares in the last quarter. 24.61% of the stock is currently owned by institutional investors.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
